Market Overview

Lazard Initiated Coverage on Vanda Pharma with a Buy Rating, $11 Price Target, Neurocrine Biosciences with a Buy and $13 PT, Repros Therapeutics with Buy, $26 PT

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Latest Ratings for VNDA

DateFirmActionFromTo
Feb 2015JefferiesMaintainsMarket Outperform
Jun 2014Empire Asset ManagementInitiates Coverage onSell
Feb 2014Piper JaffrayMaintainsOverweight

View More Analyst Ratings for VNDA
View the Latest Analyst Ratings

Posted-In: Price Target Initiation Analyst Ratings

 

Related Articles (NBIX + RPRX)

Around the Web, We're Loving...

Get Benzinga's Newsletters